These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Treatment of early Parkinson's disease: are complicated strategies justified? Ahlskog JE Mayo Clin Proc; 1996 Jul; 71(7):659-70. PubMed ID: 8656708 [TBL] [Abstract][Full Text] [Related]
4. Drug management of Parkinson's disease. Kishore A; Snow BJ Can Fam Physician; 1996 May; 42():946-52. PubMed ID: 8688697 [TBL] [Abstract][Full Text] [Related]
5. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom. Lees AJ BMJ; 1995 Dec; 311(7020):1602-7. PubMed ID: 8555803 [TBL] [Abstract][Full Text] [Related]
6. Effect of adding selegiline to levodopa in early, mild Parkinson's disease. Formal systematic review of data on patients in all relevant trials is required. Counsell C BMJ; 1998 Dec; 317(7172):1586. PubMed ID: 9836669 [No Abstract] [Full Text] [Related]
7. Effect of adding selegiline to levodopa in early, mild Parkinson's disease. Evidence is insufficient to show that combined treatment increases mortality. Aaltonen H; Kilkku O; Heinonen E; Mäki-Ikola O BMJ; 1998 Dec; 317(7172):1586-7. PubMed ID: 9890764 [No Abstract] [Full Text] [Related]
8. [Optimization of the treatment of Parkinson's disease using dopamine agonists]. Rinne UK Arch Neurobiol (Madr); 1991; 54(6):282-7. PubMed ID: 1687430 [No Abstract] [Full Text] [Related]
9. Bromocriptine versus levodopa in early Parkinson's disease. Ramaker C; van Hilten JJ Cochrane Database Syst Rev; 2000; (3):CD002258. PubMed ID: 10908538 [TBL] [Abstract][Full Text] [Related]
10. Deprenyl and levodopa and Parkinson's disease progression. Fowler JS; Fazzini E; Volkow ND Ann Neurol; 1996 Aug; 40(2):267-8. PubMed ID: 8773616 [No Abstract] [Full Text] [Related]
11. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Olanow CW; Hauser RA; Gauger L; Malapira T; Koller W; Hubble J; Bushenbark K; Lilienfeld D; Esterlitz J Ann Neurol; 1995 Nov; 38(5):771-7. PubMed ID: 7486869 [TBL] [Abstract][Full Text] [Related]
12. Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. Parkinson's Disease Research Group in the United Kingdom. BMJ; 1993 Aug; 307(6902):469-72. PubMed ID: 8400928 [TBL] [Abstract][Full Text] [Related]
13. Current and future approaches to therapy. Birkmayer W; Birkmayer JD Adv Neurol; 1987; 45():511-2. PubMed ID: 3103393 [No Abstract] [Full Text] [Related]
14. Bromocriptine/levodopa combined versus levodopa alone for early Parkinson's disease. Ramaker C; Hilten JJ Cochrane Database Syst Rev; 2002; (2):CD003634. PubMed ID: 12076493 [TBL] [Abstract][Full Text] [Related]
15. Selegiline in Parkinson's disease. Calne DB BMJ; 1995 Dec; 311(7020):1583-4. PubMed ID: 8555790 [No Abstract] [Full Text] [Related]
16. Selegiline, or the problem of early termination of clinical trials. The clinical questions are not well answered, and probably never will be. Breteler MM BMJ; 1998 Apr; 316(7139):1182-3. PubMed ID: 9552992 [No Abstract] [Full Text] [Related]
17. Selegiline: a second look. Six years later: too risky in Parkinson's disease. Prescrire Int; 2002 Aug; 11(60):108-11. PubMed ID: 12199263 [TBL] [Abstract][Full Text] [Related]